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to 6% between 2008–2013. It still lags behind NICE’s 2008 benchmark of 12%, in addi-
tion to uptake in other Western countries. We aimed to understand why the UK has 
comparatively low pump uptake. Methods: We performed a structured PubMed 
literature review using search terms “Continuous subcutaneous insulin infusion” 
AND glycaemi* OR hypoglycaemi* OR “costs and cost analysis[MeSH]”, published 
after 01/01/2008. Captured articles were sifted; excluding irrelevant articles, or those 
not in English. Other relevant reports were captured by horizon scanning. Results: 
Our search terms captured 113 articles. Reviewing reports meeting the inclusion 
criteria revealed that since 2008, additional studies contribute evidence supporting 
CSII efficacy in improving HbA1c, glycaemic variability and incidence of hypogly-
caemia compared to MDI; in addition to being well-tolerated by patients. Recent 
cost-analyses suggest that CSII remains cost-effective, especially when increasing 
baseline HbA1c, hypoglycaemia avoidance, or pump life expectancy. Furthermore, 
there may be a low availability of specialised nurses, dieticians and other clinicians 
that NICE recommends are required to form part of a CSII-specialised multi-disci-
plinary team. ConClusions: It is surprising that given the amount of evidence 
supporting the efficacy, safety and cost-effectiveness of CSII, uptake of pumps by 
T1DM patients remains low in the UK. It is interesting that current evidence may be 
undermined by poor availability of clinical staff specialised in CSII, thus preventing 
new patients from effectively managing their condition.
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objeCtives: To evaluate treatment patterns of Type 2 diabetes (T2DM) patients 
initiating glucagon-like peptide-1 receptor agonists (GLP-1) in Canada. Methods: 
Adult T2DM patients initiating a GLP-1 between January 2010 and December 2011 
were identified using the IMS retail pharmacy database (LRx). Initiation was termed 
‘index date’. Eligible patients were naïve to GLP-1 class and had ≥ 180 days pre-index 
(with ≥ 1 oral anti-hyperglycemic agent used) and ≥ 360 days post-index of patient 
and data stability. Patients were followed through December 2012. Treatment pat-
terns over the variable-follow-up, and average daily dose of the index therapy 
while persistent were assessed. Outcomes were summarized overall and by GLP-1 
therapy: exenatide twice-daily (exBID) or liraglutide (LIRA). Results: 12,417 GLP-1 
initiators, 242 exBID and 12,175 LIRA, were included, with mean (SD) follow-up of 
14.9(1.5) and 20.6(4.8) months, respectively. Overall, approximately half were male 
(49.9%) with mean (SD) age of 57.2(9.9) years at index. 70.1% GLP-1 initiators were 
privately insured; 5.0% publicly covered and 21.4% were based on out-of-pocket 
payments. In the 180 day pre-index period, 33.7% of GLP-1 initiators used two 
concomitant anti-hyperglycemic agents, 27.9% used three, 19.7% used only one, 
and 8.4% used > 3. The most frequent concomitant medications in the pre-index 
were biguanides (75%), sulfonylureas (43.9%), and DPP-IV inhibitors (24.7%). At 
index, 35.9% of GLP-1 initiators used one concomitant anti-hyperglycemic agent 
in addition to the initiated GLP-1, while 44.3% used ≥ 2. The most frequent con-
comitant medication classes were biguanide (61.1%) and sulfonylurea (30.4%). 
Co-occurring cardiovascular medications (87.2% in the pre-index; 81.1% at index) 
were commonly used, as were lipid-lowering medications, specifically (72.6% in 
the pre-index; 62.9% at index). Over the variable-length follow-up, mean(SD) daily 
dose was 19.8(3.2)µg for exBID, 1.58(0.14)mg for LIRA. ConClusions: Treatment 
patterns varied among GLP-1 patients in Canada. Longer-term data would be use-
ful to further elucidate practice patterns.
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objeCtives: 1)Compare demographic and clinical characteristics and treat-
ment patterns of anti-vascular endothelial growth factor (VEGF) (bevacizumab, 
ranibizumab, pegaptanib) and laser therapies among diabetic macular edema 
(DME) patients; 2)Determine predictors of switching and anti-VEGF therapy initia-
tion. Methods: A retrospective cohort analysis was conducted with Texas Medicaid 
medical claims (1/1/08-12/31/12) for patients who were: 18- 63 years, continuously 
enrolled one year pre- and post-index, diagnosed with DME and treated with anti-
VEGF or laser. Treatment patterns included treatment frequency and switching 
between anti-VEGF and laser. Logistic regression was used to predict switching 
and initiation of anti-VEGF while controlling for demographic (age, gender, race) 
and clinical characteristics (visual impairment, Charlson Comorbidity Index (CCI), 
number of unique prescriptions). Results: DME patients (N= 2158) were 54.7±7.8 
years, 62.7% female and 58.3% Hispanic. 9.7% were visually impaired, CCI mean 
score was 6.5±3.2 and patients were on 2.6±3.2 unique prescriptions. A higher 
(p= 0.03) percentage of females were treated with laser (63.7%) compared to anti-
VEGF (57.6%). Anti-VEGF users (1.9±3.0) had fewer (p< 0.0001) prescriptions compared 
to laser (2.7±3.2). Laser was most commonly used (84.4%); however, anti-VEGF use 
increased from 12.6% in 2009 to 23.8% in 2011 (p< 0.0001). Patients received 2.2±1.4 
laser surgeries compared to 2.4±1.8 anti-VEGF injections. Switching from laser to 
anti-VEGF was 9.6%, while anti-VEGF to laser was 42.4%. Logistic regression showed 
that switchers were more likely to be Hispanic (OR= 1.442;95%CI= 1.053-1.975), male 
(OR= 1.333;95%CI= 1.043-1.703), have fewer prescriptions (OR= 0.946;95%CI= 0.907-
0.986) and less likely to have no visual impairment (OR= 0.620;95%CI= 0.434-0.885). 
Anti-VEGF initiators were likely to be Hispanic (OR= 1.402;95%CI= 1.032-1.906), have 
fewer prescriptions (OR= 0.909;95%CI= 0.871-0.950) and initiate in 2011 vs. 2009 
(OR= 2.298;95%CI= 1.722-3.065). ConClusions: Conclusions: Although anti-VEGF 
use in increasing, laser therapy is still more prevalent. Also, slightly over 40% of 
patients who initiated on anti-VEGF switched to laser after the first treatment. 
Additional research should be conducted to determine factors associated with this 
high rate of switching.
without previous injection experience were more likely to use a support program. 
For 67% of patients using any program, the corresponding medication was the first 
injectable taken. The proportion who rated their program as extremely useful (6 
or 7 on a 7-point scale) was 57% for BSS, 54% for VC, and 68% for LC. Overall, 49% 
reported using their program for 6 months or longer. Length of utilization was high-
est for LC with 31% reporting using the program for ≥ 1 yr. The program components 
most commonly used were educational materials (used by 75%), coupons (43%), 
telephonic support (31%), and medication reminders (8%). Use of educational mate-
rials was highest for LC, use of coupons was highest for VC, and use of telephonic 
support and reminders was highest for BSS. ConClusions: Although the minority 
of patients reported using these patient-support programs, those who did use them 
reported high levels of satisfaction and relatively long engagement.
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objeCtives: The aim of this claims-based data analysis was to describe the inpa-
tient/outpatient care of German T2DM patients and to determine which subgroups 
could be differentiated in terms of the achieved T2DM-related treatment results, 
the underlying comorbidities, and the achieved comorbidity-related treatment 
results. Methods: We included all T2DM patients insured by one large sickness 
fund in 2010/2011. We defined 12 different T2DM patient subgroups according to 
observed HbA1C, blood pressure, and Charlson Comorbidity Index (CCI). For each 
subgroup, available sociodemographic information, HbA1C, blood pressure, CCI, BMI, 
kidney status, and previous micro- and macrovascular events the patients expe-
rienced were reported. Furthermore, outpatient/inpatient as well as medication 
treatment was described. T2DM related events leading to acute hospitalisations 
were reported for all subgroups. Results: We included 394,828 T2DM-patients in 
our analysis (age 73.10 years; CCI 6.86); for 228,703 patients detailed laboratory 
data as basis for subgroup classification were available. For 4.5% of the patients, 
a HbA1C> 9% was observed. Across all patient subgroups, a total of 21,833 of the 
patients involved were affected by a T2DM-related event; the risk was 5.53% per 
patient year; 1.74% of the patients suffered from more than one event. Most frequent 
event types were hospitalisation with T2DM as primary diagnosis (2.39%), vascu-
lar interventions/stent implantations (1.92%), and ischaemic stroke (1.19%). There 
were significant differences between the observed subgroups in terms of T2DM-
related event risk; belonging to a specific subgroup is an independent predictor of 
the event risk. ConClusions: Overall, our data indicate that the typically treated 
T2DM patient has a number of comorbidities and thus treatment focused solely on 
T2DM is neither possible nor clinically meaningful. Particularly those patients who 
reached HbA1C goals, but had also achieved relevant additional treatment goals 
reached low yearly T2DM event rates whereas subgroups failing to achieve one or 
several treatment goals are facing much higher event risks.
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objeCtives: Diabetes mellitus (DM) is one of the diseases with the largest health 
care expenditures, with an estimated cost of $245 billion in 2012. We assessed US 
Food and Drug Administration (FDA) approval trends and manufacturer listed prices 
at approval of diabetes medications. Methods: Regulatory data were derived from 
the FDA website and average wholesaler price (AWP) per unit from the RedBook 
(Truven Health Analytics, Inc.). Descriptive statistical methods were used in the 
analysis. Results: There were 104 medications approved for DM as of January 1, 
2014. Among them, 53% were insulins and 47% oral antidiabetes drugs (OAD). The 
FDA designated 8 orphan indications for diabetes, but not orphan designations were 
approved to date. The number of insulin approvals was higher during the 1980’s and 
the number of OAD approvals was higher between 2000 and 2009. The rate of market 
discontinuation was 75.0% for insulins and 18.4% for OAD. There were a total of 23 
OADs with generic market competition. The mean time from new drug application 
approval to abbreviated new drug application approval was 15.4 years. Mean AWP 
unit prices were $1.25 for insulins and $0.30 for OADs in the 1980’s, and increased 
to $6.45 and $12.73, respectively in the 2000’s. From the 1980s to the 2000s, OAD 
manufacturer prices at approval increased by 42 times and insulin prices increased 
by 5 times. In comparison, the consumer price index increased 2.8 times during the 
same period. ConClusions: OAD products represented the largest percentage of 
new products approved for diabetes after 2000. In contrast, the number of insulin 
approvals decreased during the same period. There were not orphan approvals 
indicating the high prevalence of DM in the US. Manufacturer listed prices increased 
at higher pace than the inflation during the study period.
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objeCtives: NICE technology appraisal TA151 (Continuous subcutaneous insulin 
infusion [CSII] for the treatment of diabetes mellitus) was issued in July 2008, replac-
ing TA57 from February 2003 and recommending uptake of CSII pumps in (1) adults 
with type 1 diabetes mellitus (T1DM) who fail to reduce HbA1c < 8.5%, or disabling 
hypoglycaemia using multiple daily injections (MDI), (2) and children without requir-
ing previous MDI-failure. CSII uptake in the UK rose to 4% between 2003–2008 and 
